Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver to bring news the company has entered into a sponsored research agreement with Ramot at Tel Aviv University to collaborate with Tel Aviv University to develop a novel, revolutionary approach to treating COVID-19 by using Cannabidiol loaded Exosomes.
Bincovich tells Proactive this will work in Phases and she discusses what the first part will look like and why they feel CBD could be effective in treating the Corona Virus.
CSE:INNO
Market: CSE
Market Cap: $29.49 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Full interview: Innocan signs deal with Hebrew university while also signing...
Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver from Toronto with news the company has signed a deal with the distribution company Active Therapeutics. This agreement allows Innocan to move into the U.K. and Ireland. Bincovich also told...
on 02/04/2020
2 min read
Prev article
2 min read
